ELOVL6 and Miyoshi myopathy: Notably, ELOVL6 expression is reduced in MM patients and cell lines resistant to bortezomib, and thus depleting ELOVL6 expression re-sensitized cells by increasing factors (ceramide species) dependent on ELOVL6, indicating its role in mediating bortezomib resistance [136].